Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Perspective Therapeutics Inc (CATX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Perspective Therapeutics's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.4900 -0.0400    -2.61%
12:10:19 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 3,161,806
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 1.4900 - 1.5400
Perspective Therapeutics 1.4900 -0.0400 -2.61%

Perspective Therapeutics Inc Company Profile

 
Get an in-depth profile of Perspective Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryHealthcare Equipment & Supplies
SectorHealthcare
Employees

91

Equity Type

ORD

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Contact Information

Address 2401 Elliott Avenue Suite 320
Seattle, 98121
United States
Phone 206-676-0900
Fax 509-267-3670

Top Executives

Name Age Since Title
Lori A. Holmes-Woods 62 2006 Chairperson of the Board
Robert Froman Williamson 58 2023 Independent Director
Frank Morich 71 2023 Independent Director
Johan M. Spoor 52 2023 CEO & Director
Heidi Henson 58 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CATX Comments

Write your thoughts about Perspective Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Randall Aamot
Randall Aamot Sep 13, 2023 1:04PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what a tragedy
Jens Tenhumberg
Jens Tenhumberg Jul 14, 2021 6:07AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any News 7%premarket ❤️
Jens Tenhumberg
Jens Tenhumberg Jun 23, 2021 9:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Fly baby fly
Jens Tenhumberg
Jens Tenhumberg May 18, 2021 7:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any News ? I wait for Goldrush
david bauer
david bauer Apr 01, 2021 8:14AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Run forest run
Dmitry Zadarozhny
Dmitry Zadarozhny Mar 17, 2021 5:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Whats going on?
Cédric Antunes
Cédric Antunes Mar 01, 2021 11:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
lucky those that got in the dip, i was there before the market crash T.T
Dmitry Zadarozhny
Dmitry Zadarozhny Mar 01, 2021 11:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Always average down and never up if you want to surpass mm
Jens Tenhumberg
Jens Tenhumberg Mar 01, 2021 10:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buy buy
Jens Tenhumberg
Jens Tenhumberg Feb 16, 2021 1:26PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buyouts ?! You know ?
Jens Tenhumberg
Jens Tenhumberg Feb 16, 2021 5:33AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Big fat money !!💸🍀
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email